P3 Health Partners reported Q3 adjusted EBITDA of $21 million and raised full-year 2026 guidance to $90 million to $110 million, with a $100 million midpoint, while year-to-date adjusted EBITDA reached $101 million.
PIII · P3 Health Partners Inc.
Substantial doubt about the company's ability to continue as a going concern.
“As a result, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date the unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q are issued.”View the 10-Q filed Nov 9, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
P3 Health Partners Inc. reported total operating revenue of 396,344 (in thousands), up 15%, and net income of 30,777 (in thousands) for the three months ended September 30, 2026.
P3 Health Partners reported third-quarter 2026 Adjusted EBITDA of $20.9 million and net income of $30.8 million, and raised its full-year 2026 Adjusted EBITDA guidance midpoint to $100 million.
P3 Health Partners Inc. registered up to 15,636,134 Class A common shares for selling-stockholder resale after warrant exercises. It receives no resale proceeds but could receive approximately $167.9 million from cash exercises.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA (loss) non-GAAP | 80.2M | Six Months Ended June 30 | — |
| Adjusted EBITDA (loss) PMPM non-GAAP | $127 | Six Months Ended June 30 | — |
| Adjusted EBITDA PMPM non-GAAP | $173 | Q2 2026 | — |
| Adjusted operating expense non-GAAP | 56.25M | Six Months Ended June 30 | — |
| At-risk members | 105,000 | Q2 2026 | — |
| Average at-risk members | 104,800 | the three months ended June 30, 2026 filing | — |
| Medical margin non-GAAP | 171.46M | Six Months Ended June 30 | — |
| Medical margin PMPM non-GAAP | $271 | Six Months Ended June 30 | — |
| Platform support costs | $26.97M | the three months ended June 30, 2026 filing | — |
| Platform support costs as % of total operating revenue | 7% | the three months ended June 30, 2026 filing | — |
| Total lives under management | 133,000 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PIII
this stock
P3 Health Partners Inc.
|
$19.61M | -22.6% | -2.8% | — | 0.2% |
|
HCA
HCA Healthcare, Inc.
|
$104.25B | +6.9% | +7.1% | 16.6 | 2.3% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$33.34B | +3.3% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$22.76B | +43.9% | +0.9% | 8.3 | 2.2% |
|
EHC
Encompass Health Corp
|
$13.83B | +32.8% | +10.5% | 22.0 | 3.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 9, 2026
- This year
- 20
P3 Health Partners Inc. reported total operating revenue of 396,344 (in thousands), up 15%, and net income of 30,777 (in thousands) for the three months ended September 30, 2026.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PIII | -32.5% | -34.8% | -79.2% | -33.0% | -22.6% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -35.1% | -33.6% | -79.7% | -32.8% | -33.3% |